NCT01525290View on ClinicalTrials.gov

Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke

PHASE3CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Stroke
Interventions
DRUG

Alteplase

Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion

DRUG

Placebo

lyophilised powder to be reconstituted as solution indistinguishable from the active drug

Trial Locations (7)

3000

Katholieke Universitet Leuven, Leuven

8000

Aarhus Universitetshospital, Aahrhus Sygehus, Aarhus

10117

Charite - Universitätsmedizin Berlin, Berlin

17007

Institut d'Investigacio Biomedica de Girona Doctor Josep Trueta, Girona

20246

University Medical Center Hamburg-Eppendorf, Hamburg

69677

Hospices Civils de Lyon, Bron

G12 8QQ

University of Glasgow, Glasgow

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT01525290 - Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke | Biotech Hunter | Biotech Hunter